Field Medical | $35,000,000 | (Jul 2, 2025)
Syntis Bio | $38,000,000 | (Jul 2, 2025)
Deeto | $12,500,000 | (Jul 2, 2025)
Certified by Founder
Lodge
Deverra Therapeutics
start up
United States
- Seattle
- 20/09/2023
- Unknown
- $2,400,000
Deverra Therapeutics is a clinical stage biotechnology company dedicated to the development of allogeneic, off-the-shelf cellular immunotherapies for on-demand treatment of patients with cancer and infectious diseases. The company has an exclusive license to a proprietary stem cell expansion and directed-differentiation platform from the Fred Hutchinson Cancer Research Center based on more than 20 years of federally funded research and data from 5 clinical trials. This platform can be used to generate a range of unmodified and modified immune cells to treat patients with cancer and infectious diseases.
- Industry Biotechnology
- Website https://www.deverratx.com/
- LinkedIn https://www.linkedin.com/company/deverra-therapeutics/about/
Talon.One | $135,000,000 | (Jul 2, 2025)
Bonx | $8,600,000 | (Jul 2, 2025)
Civ Robotics | $7,500,000 | (Jul 2, 2025)
Metafide | $3,275,000 | (Jul 2, 2025)
Genesis AI | $105,000,000 | (Jul 2, 2025)
Emerald AI | $24,500,000 | (Jul 2, 2025)
zango | $4,800,000 | (Jul 2, 2025)
Clearspeed | $60,000,000 | (Jul 1, 2025)
Foresight(US) | $5,500,000 | (Jul 1, 2025)